MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinson’s"

  • 2022 International Congress

    LRRK2 Inhibition by BIIB122: Trial designs for two efficacy and safety studies in Parkinson’s disease patients with and without LRRK2 mutations (Lighthouse and Luma)

    J. Shirvan, D. Jennings, P. Wang, R. Maciuca, S. Sahu, F. Sedarati, A. Kay, K. Fraser, S. Huntwork-Rodriguez, M. Yang, M. Levee, P. Chin, T. Dam (Cambridge, USA)

    Objective: Describe Luma and Lighthouse, two studies that investigate efficacy and safety of BIIB122, a LRRK2 inhibitor. Background: Increased LRRK2 kinase activity has been linked…
  • 2022 International Congress

    Level of glial neurotrophic factor in the blood plasma depending on the duration of Parkinson’s disease

    B. Muminov, R. Matmurodov, E. Abduqodirov (Tashkent, Uzbekistan)

    Objective: To study the level of glial neurotrophic factor in the blood plasma depending on the duration of PD. Background: Study of the biochemical aspects…
  • 2022 International Congress

    Curcumin prevented electrophysiological and behavioral alterations in a rotenone model of Parkinson’s disease

    L. Darbinyan, L. Hambardzumyan, L. Manukyan, K. Simonyan, V. Sarkisian (Yerevan, Armenia)

    Objective: This study discusses the in vivo electrophysiology of the hippocampus, behavioral correlates after rotenone intoxication. Background: Parkinson's disease is a progressive nervous system disorder…
  • 2022 International Congress

    The prevalence of helicobacter pylori in Parkinson’s disease

    N. Mansurova (Tashkent, Uzbekistan)

    Objective: to study the association between helicobacteriosis pylori (HP) and patients with Parkinson's disease Background: Helicobacter pylori is a bacterium associated with gastrointestinal diseases and…
  • 2022 International Congress

    Quantity detection of Substantia nigra hyperechogenicity based on digital image analysis for diagnosing Parkinson’s disease

    L. Gao, Z. Xue, X. Zhou (Nanchang, China)

    Objective: We aimed to apply digital analysis to quantify hyperechogenicity of Substantia nigra, and explore its clinical value for the diagnosis of PD. Background: Increased…
  • 2022 International Congress

    Effect of Aspartame on Parkinson’s Disease Progression and Severity

    D. Kushigian, O. Vaou (Boston, USA)

    Objective: The purpose of this review was to assess the current evidence regarding the effect of aspartame (APM) consumption on Parkinson’s Disease (PD) severity. Background:…
  • 2022 International Congress

    Body-first and brain-first PD animal models mimic human PD subtypes

    N. Vanden Berge, M. Pedersen, I. Klæstrup, J. Jacobsen, M. Simonsen, A. Alstrup, M. Romero-Ramos, P. Borghammer (Aarhus N, Denmark)

    Objective: Here, we aim to model body- and brain-first PD by injecting pathology in the gut and amygdala of old wild-type rats, respectively. Background: Parkinson’s…
  • 2022 International Congress

    The Effect of a Boxing Exercise Program on Laryngeal Function in People with Parkinson’s Disease

    Z. Thijs, C. Watts (Fort Worth, USA)

    Objective: This project aimed to determine the effect of a boxing exercise program on aerodynamic measures related to voice production (maximum expiratory pressure, MEP; transglottal…
  • 2022 International Congress

    Chronic administration of bitopertin, a GlyT1 inhibitor, in the dyskinetic 6-OHDA-lesioned rat model of Parkinson’s disease

    I. Frouni, W. Kang, D. Bédard, L. Desbiens, C. Kwan, A. Hamadjida, P. Huot (Montreal, Canada)

    Objective: To evaluate if, upon chronic administration, tolerance to the anti-dyskinetic effect of the glycine transporter 1 (GlyT1) inhibitor bitopertin, would develop, in the 6-hydroxydopamine…
  • 2022 International Congress

    Differences between two cognitive assessment instruments used in Parkinson’s disease in Kyrgyzstan

    E. Zhunusova, C. Shambetova, A. Il'Yazova (Bishkek, Kyrgyzstan)

    Objective: The aim of this study was to determine differences between Montreal Cognitive Assessment (MoCA) and Mini-Mental State Examination (MMSE) in PD patients from Kyrgyzstan.…
  • « Previous Page
  • 1
  • …
  • 328
  • 329
  • 330
  • 331
  • 332
  • …
  • 436
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
    • Welcome to the MDS Abstracts Site
    • Effect of marijuana on Essential Tremor: A case report
    • Advanced Search
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley